Progesterone is the hormone the ovary makes; a progestin is a synthetic molecule that acts on the same receptor but is built differently. At Longevity Benchmark, we review clinical trials and published literature to help women evaluate the evidence they discuss with a prescribing physician.
In menopausal hormone therapy, both agents provide endometrial protection against estrogen-stimulated hyperplasia when a woman has an intact uterus. Selecting between them requires balancing extensive randomised trial data for synthetic molecules against observational safety signals for micronized formulations.
The Verdict
Micronized Progesterone vs Synthetic Progestins Side by Side
| Attribute | Micronized progesterone | Synthetic progestins |
|---|---|---|
| Molecular structure | Chemically identical to endogenous human progesterone | Synthetic compounds that act on the progesterone receptor but are structurally different molecules |
| Ovarian hormone relationship | Identical molecule ground to small particle size for gastrointestinal absorption | Different molecular shape engineered to bind the progesterone receptor |
| Indication in combined therapy | Endometrial protection against estrogen-stimulated hyperplasia | Endometrial protection against estrogen-stimulated hyperplasia |
| Evaluation in the WHI randomised trial | Not tested in any arm of the trial | Medroxyprogesterone acetate was tested in the combined therapy arm |
| WHI trial breast cancer outcome | No trial data available from this study cohort | Conjugated equine estrogen plus medroxyprogesterone acetate raised incidence (hazard ratio 1.28) |
| E3N observational breast cancer relative risk | Relative risk of 1.00 (0.83 to 1.22) when combined with estrogen | Relative risk of 1.69 (1.50 to 1.91) for other progestagens with estrogen |
| VTE odds in primary care records | Not isolated in the cited BMJ dataset | Medroxyprogesterone acetate had highest odds ratio (2.10); dydrogesterone had lowest (1.18) |
| Strength of evidence base | Observational cohort data without randomized trial endpoints for cancer | Large randomised trial data from the Women's Health Initiative |
| Prescriber monitoring parameters | Adequacy of endometrial protection, bleeding patterns, and systemic tolerance | Endometrial response, bleeding patterns, metabolic parameters, and cardiovascular risk |
The Vocabulary of Progestogens
Medical literature uses the term progestogen as an umbrella category encompassing both endogenous progesterone and synthetic progestins.
Progesterone refers exclusively to the specific chemical hormone manufactured naturally by the human ovary. Micronized progesterone is that exact molecule, mechanically ground into microscopic particles so the digestive system can absorb it when taken by mouth. Our review of HRT vs BHRT explores how bioidentical formulations fit into clinical terminology.
Progestin serves as the collective name for synthetic compounds engineered to bind and stimulate the human progesterone receptor. Because these synthetic molecules differ from natural progesterone in their molecular architecture, they exhibit distinct secondary receptor activities. Clinical pharmacology categorizes synthetic progestins as possessing androgenic, nonandrogenic, or antiandrogenic effects depending on their specific chemical lineage.
Endometrial Protection in Combined Hormone Therapy
A progestogen is prescribed alongside systemic estrogen exclusively to prevent endometrial hyperplasia and uterine cancer in women who retain a uterus.
When a woman receives systemic estrogen without an accompanying progestogen, the hormone stimulates cellular proliferation in the uterine lining. Over time, persistent unopposed proliferation increases the risk of endometrial hyperplasia and adenocarcinoma. Pairing estrogen with an adequate progestogen counteracts this proliferative signal, maintaining endometrial stability.
Women who have undergone a surgical hysterectomy do not require a progestogen for endometrial safety. For women with an intact uterus, prescribers monitor bleeding patterns to evaluate whether the endometrial lining receives adequate protection. Understanding when to start HRT and reviewing the 3 stages of menopause can help patients contextualize why therapy components differ by anatomical status.
The Divergent Arms of the Women's Health Initiative
The Women's Health Initiative trial demonstrated that adding a synthetic progestin to estrogen produced conflicting breast cancer outcomes compared to estrogen alone.
In a 2002 publication by Rossouw et al., investigators reported on healthy postmenopausal women receiving conjugated equine estrogen combined with medroxyprogesterone acetate versus placebo. The trial was stopped on 31 May 2002 after a mean 5.2 years of follow-up. The test statistic for invasive breast cancer exceeded the stopping boundary, and the global index indicated that overall risks exceeded benefits.
The combined therapy arm documented specific hazard ratios: coronary heart disease 1.29 (1.02 to 1.63), invasive breast cancer 1.26 (1.00 to 1.59), stroke 1.41 (1.07 to 1.85), and pulmonary embolism 2.13 (1.39 to 3.25). Beneficial hazard ratios included colorectal cancer at 0.63 (0.43 to 0.92) and hip fracture at 0.66 (0.45 to 0.98), with total mortality at 0.98 (0.82 to 1.18). Absolute excess risks per 10,000 person-years were 7 more heart disease events, 8 more strokes, 8 more pulmonary emboli, and 8 more invasive breast cancers, with an excess global index of 19 per 10,000 person-years.
Long-term follow-up published by Chlebowski et al. in 2020 analyzed 27,347 postmenopausal women with a baseline mean age of 63.4 across both trial arms over more than 20 years of median follow-up. In 10,739 women with prior hysterectomy receiving estrogen alone, breast cancer incidence was lower at 238 versus 296 cases (hazard ratio 0.78, 0.65 to 0.93), and breast cancer mortality was lower at 30 versus 46 deaths (hazard ratio 0.60, 0.37 to 0.97). Conversely, 16,608 women with a uterus receiving estrogen plus medroxyprogesterone acetate experienced higher breast cancer incidence at 584 versus 447 cases (hazard ratio 1.28, 1.13 to 1.45), with 71 versus 53 deaths (hazard ratio 1.35, 0.94 to 1.95).
These opposing findings transformed the progestogen component from an administrative detail into a central scientific question. Investigators observed that the two study arms diverged in opposite directions on breast cancer incidence depending on whether medroxyprogesterone acetate was included. The Women's Health Initiative evaluated this specific synthetic progestin and never tested micronized progesterone in any arm.
Breast Cancer Signals in the French E3N Cohort
Prospective cohort data from the French E3N study showed that invasive breast cancer associations varied depending on which progestogen clinicians paired with estrogen.
A prospective analysis by Fournier et al. evaluated 80,377 postmenopausal women tracking 2,354 invasive breast cancers across a mean 8.1 postmenopausal years of follow-up from 1990 to 2002. Compared to women who never used hormone replacement, estrogen alone was associated with a 1.29-fold increased risk (95% CI 1.02 to 1.65). When estrogen was combined with micronized progesterone, the observed relative risk was 1.00 (0.83 to 1.22), whereas estrogen combined with dydrogesterone yielded a relative risk of 1.16 (0.94 to 1.43).
In contrast, combining estrogen with other synthetic progestagens produced an elevated relative risk of 1.69 (1.50 to 1.91). Although that category included progestins with androgenic, nonandrogenic, and antiandrogenic properties, risk estimates within the group did not differ significantly from each other. The E3N study found no evidence of an association with risk according to the route of estrogen administration, oral or transdermal or percutaneous.
The authors concluded that the choice of the progestagen component in combined therapy is of importance regarding breast cancer risk, suggesting it could be preferable to use progesterone or dydrogesterone. Patients evaluating these findings must recognize that E3N was an observational cohort rather than a randomised trial. Because women were not randomly allocated to a molecule, prescribing patterns and unmeasured confounding factors may have influenced the observed outcomes.
Venous Thromboembolism Risks across Regimens
Primary care observational records demonstrate that the odds of developing a venous thromboembolism vary substantially according to the progestogen prescribed in combined therapy.
In a comprehensive observational study using United Kingdom primary care records, Vinogradova et al. established that progestogen selection influenced vascular risk. Conjugated equine estrogen combined with medroxyprogesterone acetate carried the highest venous thromboembolism odds ratio of any evaluated regimen at 2.10 (1.92 to 2.31). In contrast, estradiol combined with dydrogesterone carried the lowest odds ratio at 1.18 (0.98 to 1.42).
These risk variations demonstrate that synthetic progestins cannot be viewed as a uniform pharmacological class regarding vascular outcomes. The route the estrogen takes is a separate question, covered in our guide to estradiol patch vs pill. Women reviewing overall safety profiles can explore our summary of HRT side effects and risks.
Gaps in the Micronized Progesterone Evidence Base
The favorable breast safety signal attributed to micronized progesterone rests on observational cohort data rather than randomised clinical trials with disease endpoints.
While observational studies like the E3N cohort report neutral breast cancer associations, no randomised trial has evaluated micronized progesterone against synthetic progestins for cancer outcomes. Randomised trials remove selection bias and unmeasured confounding, which observational cohorts cannot. Synthetic progestins like medroxyprogesterone acetate carry randomised trial documentation from the Women's Health Initiative, even if those results revealed elevated risks.
Published literature also lacks head-to-head randomized trials establishing the relative degree of endometrial protection between micronized progesterone and synthetic progestins across varying treatment durations. Professional societies, including The Menopause Society in their 2022 hormone therapy position statement, emphasize that endometrial protection remains the primary clinical requirement for any progestogen. Organizations such as the American College of Obstetricians and Gynecologists maintain that clinical oversight is necessary to confirm that whichever progestogen is chosen maintains uterine safety.
Clinical Factors Prescribers Evaluate
Prescribers evaluate several distinct clinical variables when selecting between micronized progesterone and synthetic progestins for combined hormone therapy.
Because individual medical histories and risk profiles vary, a physician does not apply a universal choice to every patient. Doctors consider baseline disease vulnerabilities, prior treatment reactions, and uterine status before writing a prescription.
- Endometrial protection verification. The clinician ensures that the prescribed progestogen adequately prevents endometrial thickening and controls abnormal uterine bleeding.
- Thrombotic and cardiovascular risk. Physicians assess baseline clotting risk, recalling that observational data from Vinogradova et al. linked medroxyprogesterone acetate to higher venous thromboembolism odds than dydrogesterone.
- Breast cancer risk considerations. Doctors evaluate personal breast health history against the E3N cohort findings and the increased incidence recorded in the combined arm of the Women's Health Initiative.
- Tolerability and bleeding control. Prescribers monitor patient response to assess symptom relief and uterine bleeding, referencing criteria discussed in our guide on is HRT working.
- Formulary access and availability. Practitioners consider insurance coverage, pharmacy availability, and standardized manufacturing when determining appropriate therapy, often cross-referencing options in our guide to the best hormone therapy for women.
Frequently Asked Questions
What is the difference between progesterone and a progestin?
Progesterone is the exact hormone produced by the human ovaries, whereas a progestin is a synthetic compound designed to stimulate the progesterone receptor. Micronized progesterone has the identical molecular shape as ovarian progesterone, processed into small particles so the digestive system can absorb it. Synthetic progestins, such as medroxyprogesterone acetate or dydrogesterone, feature altered chemical structures. These structural differences give them distinct secondary activities, which researchers categorize as androgenic, nonandrogenic, or antiandrogenic effects.
Is micronized progesterone safer than a synthetic progestin?
Clinical studies show different risk patterns for micronized progesterone and synthetic progestins, but neither medication can be described simply as safe. In the observational French E3N cohort, women taking estrogen combined with micronized progesterone had a breast cancer relative risk of 1.00 compared to non-users, while estrogen paired with other synthetic progestins showed a relative risk of 1.69. However, the favorable signal for micronized progesterone comes from observational studies rather than randomised clinical trials. Synthetic progestins have extensive randomised trial evidence from the Women's Health Initiative, but that trial showed increased breast cancer and cardiovascular events.
Did the Women's Health Initiative test micronized progesterone?
No, the Women's Health Initiative did not evaluate micronized progesterone in any arm of its clinical trials. The combined hormone therapy arm of the trial tested conjugated equine estrogen paired specifically with medroxyprogesterone acetate, a synthetic progestin. That arm was halted early in 2002 after investigators observed that invasive breast cancer rates exceeded the trial's safety boundary. Because micronized progesterone was never administered in the trial, the Women's Health Initiative cannot provide direct evidence regarding the benefits, risks, or clinical efficacy of bioidentical progesterone.
Why did the estrogen-only arm of the WHI show lower breast cancer incidence?
In the Women's Health Initiative long-term follow-up, postmenopausal women with prior hysterectomy receiving conjugated equine estrogen alone experienced significantly lower breast cancer incidence than women receiving placebo. In the 2020 follow-up by Chlebowski et al., estrogen alone was associated with a hazard ratio of 0.78 for breast cancer incidence and 0.60 for breast cancer mortality. In contrast, the trial arm testing estrogen combined with medroxyprogesterone acetate showed a significantly higher breast cancer incidence with a hazard ratio of 1.28. The two arms differed in the progestogen and went in opposite directions on breast cancer incidence. That is what turned the progestogen component into a research question rather than an afterthought.
Does the type of progestogen change blood clot risk?
Yes, observational data show that venous thromboembolism risk varies substantially depending on the specific progestogen molecule paired with estrogen. In a large primary care database study published by Vinogradova et al. in the BMJ, conjugated equine estrogen combined with medroxyprogesterone acetate showed the highest venous thromboembolism odds ratio at 2.10. Conversely, estradiol combined with dydrogesterone carried the lowest odds ratio at 1.18. These findings demonstrate that different progestin compounds possess distinct vascular profiles, making the selection of the individual progestogen clinically significant when evaluating thrombotic risk.
Is natural progesterone the same as bioidentical progesterone?
Natural progesterone and bioidentical progesterone refer to the same chemical molecule, which possesses a molecular structure identical to the hormone produced by human ovaries. The medical term for this compound in prescription therapy is micronized progesterone. The term natural is often used in public discussions because the molecule mirrors human biology, while bioidentical describes the identical molecular configuration. Clinicians generally use the pharmacological term micronized progesterone to distinguish approved pharmaceutical formulations from custom-compounded products, which we discuss in our comparison of HRT vs BHRT.
Do you still need a progestogen if you use an estrogen patch?
Yes, any woman with an intact uterus who receives systemic estrogen requires a progestogen for endometrial protection, regardless of whether she uses a patch or a pill. Systemic estrogen delivered through the skin reaches the bloodstream, and endometrial protection is the reason a progestogen is in the prescription at all. Without an adequate progestogen to prevent estrogen-induced proliferation, the risk of endometrial hyperplasia rises.
Is the evidence for progesterone from randomised trials?
No, the evidence suggesting that micronized progesterone carries lower breast cancer risks than synthetic progestins comes from observational cohort studies rather than randomised trials. The primary data supporting this distinction originate from large observational investigations, such as the French E3N study of over 80,000 postmenopausal women. Observational studies give population-level signals, but they cannot control for all potential biases or prove cause and effect the way randomised trials do. No randomised trial on published record has tested micronized progesterone against synthetic progestins for cancer or mortality endpoints.